Cumberland (CPIX) Pharmaceuticals announced that its ibuprofen injection product has received regulatory approval in Mexico. The approval follows Cumberland’s partnership with PiSA Farmaceutica, which includes exclusive supply and distribution rights for the ibuprofen product in the Mexican market. PiSA is a well-established Mexican pharmaceutical firm with a leading injectable business in that country. Under the agreement, Cumberland is providing regulatory and manufacturing support, while PiSA led the regulatory process and will now launch the product in Mexico.PiSA plans to introduce the product in 800 mg vials, making it accessible for a variety of clinical uses in Mexican healthcare facilities.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CPIX:
- Cumberland announces launch of Vibativ injection in Saudi Arabia
- Cumberland Pharmaceuticals Advances IPF Treatment with Ifetroban Study
- Cumberland Pharmaceuticals’ Earnings Call Highlights Growth and Expansion
- Cumberland Pharmaceuticals Reports Strong Revenue Growth
- Cumberland announces availability of Vibativo 4-Vial Starter Pak through Vizient